Dr. Austin Miller Dr. Austin Miller

Austin Miller

PhD

Special Interests:

The design and analysis of experimental, clinical and observational studies, measurement error models and structural equations modeling.

About Me

Biography:

Dr. Austin Miller earned his PhD in Biostatistics and MA in Biostatistics from the SUNY University at Buffalo (UB).

Dr. Miller joined the Department of Biostatistics and Bioinformatics at Roswell Park Comprehensive Cancer Center (Roswell Park) as an assistant professor in 2008. He has designed, reviewed and analyzed many clinical trials, mouse studies and translational research for various disease settings and outcomes. He is currently a member of the Scientific Review Committee and a Data Safety Monitoring Committee. He is also working with the Gynecologic Oncology Group (GOG) statistical and data center on the design, management and analysis of larger-scale clinical trials. 


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Department of Biostatistics and Bioinformatics
  • Survey Research Shared Resource Director

Background

Education and Training:

  • PhD - State University of New York at Buffalo
  • MA - State University of New York at Buffalo
  • MS - Carnegie Mellon University, Pittsburgh PA
  • BS - University of Southern California, Los Angeles

Research

Research Overview:

Dr. Miller regularly collaborates with RPCI Members and Fellows from a broad array of disciplines. His statistical expertise supports development of grant submissions, experimental designs involving cell-line, animal or human subjects, review and analysis of data, and contributes to peer-reviewed manuscripts and poster presentations. Much of his work has involved assessment of immune responses to cancer and treatments, and how those immune responses impact patient prognosis. Other collaborations have included epidemiologic studies, development of early-stage cancer screening methods, and assessments of quality control interventions for nurses and pharmacists.


Publications

Matsuzaki J, Old LJ, Shrikant P, Lele S, Qian F, Eppolito C, Tsuji T, Miller A, Beck A, Mhawech-Fauceglia P, Gnjatic S, Odunsi K. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2010; 107(17):7875-7880

Godoy HE, Mhawech-Fauceglia P, Beck Amy, Miller A, Lele S, Odunsi K.Expression of poly(adenosine diphosphate-ribose) polymerase (PARP) and p53 in epithelial ovarian cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:192

Miller C, Rose S, Staney M, Brady M, Miller A, Krivak T, Chernofsky M, Farley J, Hamilton C, Maxwell G. The impact of disease distribution on survival in patients with advanced-stage epithelial ovarian cancer cytoreduced to microscopic residual: A Gynecologic Oncology Group study. Gynecologic Oncology 2010; 116(3 Suppl. 1):35

Cox DD, Miller A, Edge S, Kuvshinoff B. Regionalization of pancreatic resection for malignancy in NY State and the effect of hospital volume on perioperative mortality. Annals of Surgical Oncology 2010; 17(Suppl. 1):S80

Lillard S, Watroba N, Miller A, Kulkarni S, Edge S. Early stage breast cancer in elderly women - Can radiation therapy safely be withheld outside of a clinical trial setting?. Annals of Surgical Oncology 2010; 17(Suppl. 1):S54

May KS , Miller A , Fung-Kee-Fung SD , Singh AK. Salivary infiltrating ductal carcinoma: SEER database analysis of the impact of surgery, radiation, and lymph node involvement on survival. International Journal of Radiation Oncology, Biology, Physics 2010; 78(3 Suppl. 1):S457

Brady MT, Miller A, Sait S, Ford LA, Hans M, Wang ES, Lee KP, Baumann H, Wetzler M. Down-regulation of signal transducer and activator of transcription 3 enhances acute myeloid leukemia-derived dendritic cell function. Blood 2010; 116(21):3140

Ademuyiwa FO, Miller A, Edge SB, Thorat MA, Sledge GW, Badve SS. The effects of Oncotype DX recurrence scores on chemotherapy receipt in a multi-institutional breast cancer cohort. Journal of Clinical Oncology 2010; 28(15 Suppl.):669

Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Research and Treatment 2011; 126(3):797-802

Godoy H, Mhawech-Fauceglia P, Beck A, Miller A, Lele S, Odunsi K.Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome. International Journal of Gynecological Pathology 2011; 30(2):139-144

Thatikonda C, Miller A, Iyer R. Meta analysis of oxaliplatin-based combination chemotherapy for advanced gallbladder and bile duct cancers (AGBC). American Journal of Gastroenterology 2010; 105(Suppl. 1):194

Akers S, Moysich K, Zhang W, Link P, Miller A, Lele S, Odunsi K, Karpf A.Association between global DNA hypomethylation in leukocytes and risk of ovarian cancer. Gynecologic oncology 2011; 121(1 Suppl.):100

Chanan-Khan A, Zeldis JB, Wallace PK, Czuczman MS, Hernandez-Illatazurri F, Miller A, Padmanabhan S, Lawrence D, Miller KC, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011; 117(10):2127-2135

Wolinsky JS, Ladkani D, Kadosh S, Pardo L, Miller A, Johnson K, Ford C, Coyle PK, O'Connor P, Narayana PA, PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Annals of Neurology 2007; 61(1):14-24

Hamilton CA, Armstrong DK, Ozols RF, Markman M, Rose GS, Stany MP, Chernofsky MR, Farley JH, Krivak TC, Miller C, Miller A, Maxwell GL. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecologic Oncology 2011; 122(3):521-526

Chadha K, Thatikonda C, Miller A, Nava H, Sitrin M, Hicks W, Rigual N, Loree T, Schiff M. Outcomes of Percutaneous Endoscopic Gastrostomy Tube Placement using the Brown-Muller T-fastener Technique in Head, Neck and Esophageal Cancer patients. American Journal of Gastroenterology 2009; 104(Suppl. 3):Abstract #1351

Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: A Gynecologic Oncology Group study. Gynecologic Oncology 2012; 124(1):53-58

Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PloS One 2011; 6(11):e27690

Hennon MW, Hylander B, Morrison C, Miller A, Groman A, Dexter E, Yendamuri S, Demmy TL, Adjei A, Reid M, Repasky E, Nwogu C. Predicting NSCLC outcomes based on tumor growth in SCID mice. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1610

Nwogu CE, Groman A, Fahey D, Yendamuri S, Dexter E, Demmy TL, Miller A, Reid M. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Annals of Thoracic Surgery 2012; 93(5):1614-1619; discussion 1619-1620

Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, Lele S, DuPont N, Edwards R, Shrikant P, Old LJ, Gnjatic S, Jager E. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(15):5797-5802

Richard S, Miller A, Markman M, Armstrong D, Walker J, Krivak T. Nadir CA125 and second look surgery in patients with advanced stage epithelial ovarian cancer treated with intravenous compared to intraperitoneal chemotherapy: A study of Gynecologic Oncology Group Protocols 114 and 172. Gynecologic Oncology 2012; 125(Suppl. 1):S28-S29

Rodriguez N, Miller A, Richard S, Rungruang B, Hamilton C, Bookman M, Maxwell G, Horowitz N, Krivak T. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: An analysis of GOG 182. Gynecologic Oncology 2012;125(Suppl. 1):S23-S24

Rungruang B, Miller A, Richard S, Rodriguez N, Bookman M, Hamilton C, Maxwell G, Horowitz N, Krivak T. Advanced stage ovarian cancer - Does complex surgery improve survival? An analysis of GOG 182. Gynecologic Oncology 2012; 125(Suppl. 1):S23

Allamaneni SS, Sharma R, Miller A, Yendamuri SS, Gibbs JF. Additional primary malignancies in patients with pancreatic cancer : 2012 Gastrointestinal Cancers Symposium. Journal of Clinical Oncology 2012; 30(4 Suppl.):Abstract #185

O'Cearbhaill RE, Miller A, Muggia F, Smith JA, Bookman MA, Sabbatini P, Gynecologic Oncology Group. Carboplatin dosing in the treatment of epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study : ASCO Meeting Abstracts Part 1. Journal of Clinical Oncology 2012; 30(15 Suppl.):Abstract #5041

Yendamuri S, Caty L, Pine M, Adem S, Bogner P, Miller A, Demmy TL, Groman A, Reid M. Outcomes of sarcomatoid carcinoma of the lung: A Surveillance, Epidemiology, and End Results database analysis. Surgery 2012; 152(3):397-402